Cytomegalovirus (CMV) infection in patients receiving either alemtuzumab (CAMPATH 1-H) or antithymocyte globulin (ATG) as graft-versus-host disease (GVHD) prophylaxis prior to allogeneic stem cell transplantation (SCT)

✍ Scribed by W.G. Hunt; G.R. May; R.A. Krance; H.E. Heslop; B. Catherine; I. Kuehnle

• Book ID: 116277705
• Publisher: Elsevier Science
• Year: 2004
• Tongue: English
• Weight: 58 KB
• Volume: 10
• Category: Article
• ISSN: 1083-8791
• DOI: 10.1016/j.bbmt.2003.12.169